Inhibition of the IRE1α/XBP1s branch alone or in combination with immune checkpoint blockade provides a therapeutic strategy for several cancer types with frequent coactivator-associated arginine methyltransferase 1 (CARM1) overexpression, including OC44. Here, CARM1 is linked to cancer.